Pasithea Therapeutics (KTTA) Free Cash Flow (2021 - 2026)
Pasithea Therapeutics recorded quarterly Free Cash Flow of -$4.8 million in Q1 2026, up 11.3% quarter-over-quarter from -$5.4 million in Q4 2025, and down 56.66% year-over-year from -$11.0 million in Q1 2025.
Pasithea Therapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 56.66% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$16.9 million (down 33.85% YoY), while the FY2025 annual figure was -$15.2 million, down 9.25% from the prior year.
- Free Cash Flow came in at -$4.8 million for Q1 2026 at Pasithea Therapeutics, up from -$5.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.9 million in Q2 2022 to a low of -$5.4 million in Q4 2025.
- A 5-year average of -$3.5 million and a median of -$3.3 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow tumbled 743.68% in 2022 and soared 30.51% in 2023, its largest moves.
- Pasithea Therapeutics' Free Cash Flow stood at -$3.3 million in 2022, then dropped by 0.49% to -$3.3 million in 2023, then climbed by 25.84% to -$2.4 million in 2024, then plunged by 120.91% to -$5.4 million in 2025, then grew by 11.3% to -$4.8 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$4.8 million, -$5.4 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -4.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.79 Mn |
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | -3.87 Mn |
| Mar 31, 2025 | -3.06 Mn |
| Mar 31, 2025 | -3.06 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Dec 31, 2023 | -3.29 Mn |
| Dec 31, 2023 | -3.29 Mn |
| Sep 30, 2023 | -3.22 Mn |
| Sep 30, 2023 | -3.22 Mn |
| Jun 30, 2023 | -3.08 Mn |
| Jun 30, 2023 | -3.08 Mn |
| Mar 31, 2023 | -3.26 Mn |
| Mar 31, 2023 | -3.26 Mn |
| Dec 31, 2022 | -3.28 Mn |
| Dec 31, 2022 | -3.28 Mn |
| Sep 30, 2022 | -4.63 Mn |
| Sep 30, 2022 | -4.63 Mn |
| Jun 30, 2022 | -1.94 Mn |
| Jun 30, 2022 | -1.94 Mn |
| Mar 31, 2022 | -2.15 Mn |
| Mar 31, 2022 | -2.15 Mn |
| Dec 31, 2021 | -1.76 Mn |
| Dec 31, 2021 | -1.76 Mn |
| Sep 30, 2021 | -548,442.00 |
| Sep 30, 2021 | -548,442.00 |
| Jun 30, 2021 | -499,438.00 |
| Jun 30, 2021 | -499,438.00 |
| Mar 31, 2021 | -381,845.00 |
| Mar 31, 2021 | -381,845.00 |